Castle Biosciences

244 articles with Castle Biosciences

• Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting

  8/6/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that data on two of its skin cancer gene expression profile tests will be featured in oral presentations during the 2021 American Academy of Dermatology Summer Meeting, being held Aug. 5-8, 2021.

• Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the DERM2021 NP/PA CME Conference

  8/5/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced data presentations on two of its skin cancer gene expression profile tests at the DEF Essential Resource Meeting NP/PA CME Conference, taking place from Aug. 5-8, 2021.

• Castle Biosciences Collaborates with the Melanoma Research Foundation

  8/2/2021

  Castle Biosciences, Inc. announced its continued collaboration with the Melanoma Research Foundation, a non-profit organization leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy.

• Castle Biosciences to Participate at the Canaccord Genuity 41st Annual Growth Conference

  7/28/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, Aug. 11, 2021, at 3:30 p.m. Eastern time.

• Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021

  7/26/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that it will release its financial results for the second quarter and six months ended June 30, 2021, after the close of market on Monday, Aug. 9, 2021.

• 

  BioSpace Movers & Shakers, July 23

  7/23/2021

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

  7/23/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced a podium presentation on its DecisionDx®-SCC test at the American Head & Neck Society 10th International Conference on Head and Neck Cancer, being held July 22-25, 2021.

• Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021

  7/22/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced data presentations on two of its skin cancer gene expression profile tests at the Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2021, taking place from July 22-25, 2021.

• Castle Biosciences Expands its Board of Directors with New Appointments

  7/16/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately.

• Castle Biosciences is Listed in the Houston Chronicle’s “CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston

  6/21/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced it has been included in the Houston Chronicle’s list of the 100 most successful publicly traded companies in the Houston area.

• Castle Biosciences to Participate at the Baird 2021 Healthcare ESG Symposium

  6/7/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Baird 2021 Healthcare ESG Symposium on June 17, 2021, at 11:20 a.m. Eastern time.

• Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

  6/1/2021

  On May 28, 2021, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.

• Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters

  5/24/2021

  Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced it will host a ribbon cutting ceremony and reception for national, state and local officials, employees and other members of the community, at its new corporate headquarters on May 25, 2021, from 3:00 p.m. – 6:00 p.m. Central time.

• Castle Biosciences Supports the American Skin Association with Research Grant

  5/21/2021

  The ASA Castle Biosciences Research Grant Melanoma was awarded to Joel Sunshine, M.D., Ph.D., Johns Hopkins School of Medicine

• Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors

  5/20/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert panel in the Journal of Drugs in Dermatology.

• Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit

  5/19/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that management will participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit, May 26, 2021. Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, will provide a pre-recorded investor presentation

• Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors

  5/11/2021

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced that Tiffany Olson has been appointed to its board of directors, effective immediately.

• Castle Biosciences Announces First Quarter 2021 Results

  5/10/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, today announced its financial results for the first quarter ended March 31, 2021.

• Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions

  5/10/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its innovative pipeline initiative to develop a genomic test aimed at predicting systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions.

• Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program

  5/6/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, has been selected as the winner of the “Best New Technology Solution for Oncology” award in the fifth annual MedTech Breakthrough Awards program.